Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Astellas Links Up with US Biotech Potenza on Immuno-Oncology
April 23, 2015
- Shionogi Ups FY2014 Earnings Outlook on ViiV Dividends
April 23, 2015
- Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
- Sales Rep Survey - Part 2: Japanese Drug Makers Forging Specialized Forces in Oncology
April 23, 2015
- Daiichi Sankyo Sells All Shares of Sun Pharma
April 22, 2015
- Merck KGaA, Pfizer Start Multinational PIII Study of Anti-PD-L1 Antibody Avelumab
April 22, 2015
- Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
- Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
- Asahi Kasei Pharma Pulls Plug on Liquid Diet Biz
April 21, 2015
- Takeda, Keio, Niigata Univs in Tripartite Research Pact on RNA-Binding Proteins
April 21, 2015
- AbbVie’s Hepatitis C Drug Gets Priority Review in Japan
April 20, 2015
- Nicholas Grund to Come Back as Genzyme Japan President after 8 Months
April 20, 2015
- Takeda’s iPS Cell Deal Potential Game Changer in Drug Research
April 20, 2015
- 60% of 56 Drug Makers Increase Hiring of New Graduates in FY2015; Eisai Resumed Hiring
April 20, 2015
- Ajinomoto to Resume Hiring New Graduates: FY2016 Recruitment Plan
April 20, 2015
- Baxter Files NDA for Advate Successor in Japan
April 17, 2015
- Autologous Cultured Cartilage JACC Becomes Available Across Japan: J-TEC
April 17, 2015
- Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
- Japan’s Generic Market Projected to Top 900 Billion Yen in 2017: Fuji Keizai
April 16, 2015
- JCR Successfully Develops Blood-Brain Barrier-Passing Technology; First Application to Be Drug for Hunter Syndrome
April 16, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…